Natalizumab
- TRADE NAME: Tysabri (Biogen)
- INDICATIONS: Multiple sclerosis, Crohn's disease
- SYNONYM: antegren
- CLASS: Immunomodulator, Monoclonal antibody
- HALF-LIFE: 11 days
Abatacept, Alefacept, Azacitidine, Azathioprine, Betamethasone, Cabazitaxel, Certolizumab, Cortocosteroids, Cyclosporine, Denileukin, Docetaxel, Fingolimod, Gefitinib, Leflunomide, Lenalidomide, Mercaptopurine, Methotrexate, Oxaliplatin, Pazopanib, Pemetrexed, Pralatrexate, Rilonacept, Temsirolimus, Triamcinolone, Vedolizumab
PREGNANCY CATEGORY: C
Contra-indicated in patients who have or have had progressive multifocal leukoencephalopathy.
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of natalizumab in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/03/2022
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
